Outcomes of guideline-based medical therapy in patients with acute heart failure and reduced left ventricular ejection fraction: Observations from the Gulf acute heart failure registry (Gulf CARE). Issue 23 (10th June 2022)

• Record Type: Journal Article
• Authors: Jan, Reem K.; Alsheikh-Ali, Alawi; Mulla, Arif Al; Sulaiman, Kadhim; Panduranga, Prashanth; Al-Mahmeed, Wael; Bazargani, Nooshin; Al-Suwaidi, Jassim; Al-Jarallah, Mohammed; Al-Motarreb, Ahmed; Salam, Amar; Al-Zakwani, Ibrahim
• Is Part Of: Medicine. Volume 101:Issue 23(2022)
• Page Start: e29452
• Publication Date: 2022-06-10
• Subjects: drug therapy -- guideline adherence -- heart failure -- Middle East -- reduced ejection fraction -- registry -- survival; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000029452
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: This study aimed to report on the use, predictors and outcomes of guideline-based medical therapy (GBMT) in patients with acute heart failure (HF) with reduced ejection fraction of <40% (HFrEF), from seven countries in the Arabian Gulf. Patients with acute HFrEF (N = 2680), aged 18 years or older, and hospitalized February–November 2012 were recruited and data were collected post discharge at 3 months (n = 2477) and 1 year (n = 2418). The use and doses of GBMT were evaluated as per European, American and Canadian HF guidelines. Analyses were performed using multivariate logistic regression. This study was registered at clinicaltrials.gov (NCT01467973). The majority of patients were on dual (39%) and triple (39%) GBMT modalities, 14% received one GBMT medication, while 7.2% were not on any GBMT medications. On admission, 80% of patients were on renin-angiotensin system (RAS) blockers, 75% on b-blockers and 56% on mineralocorticoid receptor antagonists (MRAs), with a small proportion of these patients were taking target doses (RAS blockers 13%, b-blockers 7.3%, MRAs 14%). Patients taking triple GBMT were younger ( P < .001), less likely to have comorbidities such as diabetes mellitus ( P < .001) and CKD/dialysis ( P < .001), less likely to receive in-hospital invasive treatments ( P < .001), and more likely to be treated by a cardiologist ( P < .001), than patients on a single medication. Patients taking triple GBMT showed significantly reduced all-cause mortality both at 3-months ( P = .048), and at 12-months ( P = .003), compared to patients taking no GBMT. Triple GBMT prescribing and dosing in patients with HFrEF were suboptimal in the Arabian Gulf. Further studies are required to investigate GBMT utilization and dosing in the outpatient setting.